drugset / Trial / NCT02740829

Assessment of Intranasal Glucagon on Endogenous Glucose Production

NCT02740829

Phase 1 Completed 10 enrolled University Health Network, Toronto
RandomizedParallel-groupSingle-blindTreatment

Summary

Peripheral glucagon action increases hepatic glucose production. In rodents hypothalamic action of glucagon paradoxically suppresses glucose production. Intranasally administered peptides have been shown to preferentially enter the central nervous system. We assessed the effects of intranasal glucagon on hepatic glucose production

Timeline

Start
2015-03
Primary completion
2016-01
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucagon Peptide 1 mg Intranasal

Indications